Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary or secondary hip osteoarthritis who are scheduled for cemented total hip replacement at the Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.~* Written informed consent is obtained from the patient or the legally accepted representative.~Exclusion Criteria:~* Patients with rheumatoid arthritis, ankylosing spondylitis, or femoral neck fractures~* Patients with previous allergic reaction on non-steroidal anti-inflammatory drugs~* Patients with gastrointestinal complaints at admission, a history of gastrointestinal ulcers or perforations, inflammatory bowel-disease, hepatic dysfunction, renal dysfunction with a clearance below 30 ml/min and cardiac insufficiency.~* Patients with blood pressure consistently \> 140/90 mmHg and who have not been adequately controlled.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Drug: Etoricoxib (Arcoxia, MSD), 90 mg. (Type: EXPERIMENTAL): Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.

Based on this trial design, predict the completion outcome and termination type (if applicable).